Sobotka T J
Center for Food Safety and Applied Nutrition, Food and Drug Administration, Washington, D.C. 20204.
Toxicol Ind Health. 1989 Mar;5(2):157-64. doi: 10.1177/074823378900500202.
One of the primary features of the mission of the Food and Drug Administration is to assure with reasonable certainty that no harm will result from the intended use of chemicals added to food. In carrying out this mission the FDA uses a structured process to assess the safety of each food chemical. The detailed mechanics of this process are described in an FDA document entitled "Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Use in Food" (Food and Drug Administration, 1982). Central to its evaluation the FDA requires a collective set of information, including estimates of the anticipated human exposure to the food chemical and a broad-based toxicological profile. Certainly, any adverse effect observed in the nervous system is recognized as an important element in the determination of chemical safety and follow-up information which would enable an assessment of such an effect to be included in the toxicological profile. The agency's current approach to evaluating neurotoxicity should be viewed within the context of its overall strategy for the safety assessment of food chemicals. Four basic premises underlie the FDA's approach to safety assessment.
美国食品药品监督管理局(FDA)使命的主要特征之一是合理确定添加到食品中的化学物质在预期使用时不会造成危害。在执行这一使命过程中,FDA采用结构化流程来评估每种食品化学物质的安全性。这一流程的详细机制在FDA一份题为《用于食品中直接食品添加剂和色素添加剂安全性评估的毒理学原则》(美国食品药品监督管理局,1982年)的文件中有描述。FDA评估的核心要求是一套综合信息,包括对人类预期接触该食品化学物质的估计以及广泛的毒理学概况。当然,在神经系统中观察到的任何不良反应都被视为确定化学物质安全性的重要因素,后续信息应能使对这种影响的评估纳入毒理学概况。该机构目前评估神经毒性的方法应在其食品化学物质安全性评估总体战略的背景下看待。FDA的安全性评估方法有四个基本前提。